ORINY.US Orion Oyj ADR

Healthcare Pharmaceuticals USA Stocks
57.89 USD
Close of Nov 15, 2026
33.69 58.15
Market cap
USD 16.2B
P/E
21.3x
P/B
10.47x
ROE
38.0%
Dividend yield
1.76%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is ORINY.US undervalued?

Graham number

The Graham number of Orion Oyj ADR cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Orion Oyj ADR fundamental analysis

No fundamental analysis for Orion Oyj ADR yet.

Orion Oyj ADR stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Orion Oyj ADR

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. It offers pharmaceutical products, which includes Nubeqa for the treatment of prostate cancer; Entacapone, Stalevo, Comtess, and Comtan to treat Parkinson's disease; Burana for inflammatory pain; Divina series for menopausal symptoms; Simdax for acute decompensated heart fa…

Full company profile